dc.contributor.author | Jones, Tanya | |
dc.contributor.author | Van Breda, Karin | |
dc.contributor.author | Charles, Bruce | |
dc.contributor.author | Dean, Angela J | |
dc.contributor.author | McDermott, Brett M | |
dc.contributor.author | Norris, Ross | |
dc.date.accessioned | 2017-05-03T13:48:05Z | |
dc.date.available | 2017-05-03T13:48:05Z | |
dc.date.issued | 2009 | |
dc.date.modified | 2010-08-13T07:24:03Z | |
dc.identifier.issn | 0269-3879 | |
dc.identifier.doi | 10.1002/bmc.1204 | |
dc.identifier.uri | http://hdl.handle.net/10072/30219 | |
dc.description.abstract | A simple, rapid, selective, accurate and precise method is described for the determination of risperidone and its active metabolite, 9-hydroxyrisperidone, in plasma using a chemical derivative of risperidone (methyl-risperidone) as the internal standard. The sample workup involved a single-step extraction of 1 mL plasma, buffered to pH 10, with heptane-isoamyl alcohol (98:2 v/v), then evaporation of the heptane phase and reconstitution of the residue in mobile phase. HPLC separation was carried out at on C18 column using a mobile phase of 0.05 m dipotassium hydrogen orthophosphate (containing 0.3% v/v triethylamine) adjusted to pH 3.7 with orthophosphoric acid (700 mL), and acetonitrile (300 mL). Flow rate was 0.6 mL/min and the detection wavelength was 280 nm. Retention times were 2.6, 3.7 and 5.8 min for 9-hydroxy risperidone, risperidone and the internal standard, respectively. Linearity in spiked plasma was demonstrated from 2 to 100 ng/mL for both risperidone and 9-hydroxyrisperidone (r = 0.999). Total imprecision was less than 13% (determined as co-efficient of variation) and the inaccuracy was less than 12% at spiked concentrations of 5 and 80 ng/mL. The limit of detection, determined as three times the baseline noise, was 1.5 ng/mL. Clinical application of the assay was demonstrated for analysis of post-dose (0.55-4.0 mg/day) samples from 28 paediatric patients (aged 6.9-17.9 years) who were taking risperidone orally for behavioural and emotional disorders. | |
dc.description.peerreviewed | Yes | |
dc.description.publicationstatus | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | John Wiley & Sons Ltd. | |
dc.publisher.place | United Kingdom | |
dc.relation.ispartofstudentpublication | N | |
dc.relation.ispartofpagefrom | 929 | |
dc.relation.ispartofpageto | 934 | |
dc.relation.ispartofissue | 9 | |
dc.relation.ispartofjournal | Biomedical Chromatography | |
dc.relation.ispartofvolume | 23 | |
dc.rights.retention | Y | |
dc.subject.fieldofresearch | Analytical chemistry | |
dc.subject.fieldofresearch | Analytical chemistry not elsewhere classified | |
dc.subject.fieldofresearch | Pharmacology and pharmaceutical sciences | |
dc.subject.fieldofresearchcode | 3401 | |
dc.subject.fieldofresearchcode | 340199 | |
dc.subject.fieldofresearchcode | 3214 | |
dc.title | Determination of risperidone and 9-Hydroxyrisperidone using HPLC, in plasma of children and adolescents with emotional and behavioural disorders | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dc.type.code | C - Journal Articles | |
gro.faculty | Griffith Health, School of Pharmacy | |
gro.date.issued | 2009 | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Jones, Tanya | |